GlassScriptPhysician profile
Ramin Sabahi
NPI 1568569804
$13,246.74
in general payments reported to CMS, 2019-2025
33 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,688 · 2020: $2,816 · 2021: $2,782 · 2022: $2,472 · 2023: $249 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $240 · Consulting Fee: $150 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.75 |
| Consulting Fee | $150.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,105.23 | 2019-2025 | Tavneos |
| Cardinal Health 108 LLC | $1,561.61 | 2019 | |
| Abbvie INC. | $1,421.92 | 2019-2022 | |
| Lilly USA, LLC | $1,214.78 | 2019-2022 | |
| Pfizer INC. | $1,124.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $840.11 | 2019-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $559.45 | 2020-2023 | Acthar |
| Genzyme Corporation | $502.63 | 2019-2021 | |
| Horizon Therapeutics Plc | $459.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $453.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $429.49 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $335.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.02 | 2019-2022 | |
| Genentech USA, INC. | $271.56 | 2019-2020 | |
| Janssen Biotech, INC. | $268.98 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $230.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $171.80 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $120.72 | 2020-2021 | |
| Intuitive Surgical, INC. | $119.82 | 2025 | |
| Aurinia Pharma U.S., INC. | $115.94 | 2021-2022 | |
| Ucb, INC. | $111.83 | 2019-2022 | |
| United Therapeutics Corporation | $100.14 | 2021 | |
| Radius Health, INC. | $67.69 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $65.78 | 2022 | |
| Pacira Therapeutics, INC. | $60.37 | 2020 | |
| Sobi, INC | $55.12 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $49.02 | 2022 | |
| Antares Pharma, INC. | $40.40 | 2021 | |
| Hikma Pharmaceuticals USA | $32.92 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $18.55 | 2021 | |
| Celgene Corporation | $15.75 | 2019 | |
| Almatica Pharma LLC | $14.92 | 2022 | |
| Boston Scientific Corporation | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Sabahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.